pompe disease enzyme replacement therapy

pompe disease enzyme replacement therapy represents a groundbreaking advancement in the treatment of Pompe disease, a rare genetic disorder characterized by the buildup of glycogen in the body's cells. This accumulation occurs due to a deficiency of the enzyme acid alpha-glucosidase (GAA), leading to progressive muscle weakness and respiratory difficulties. Enzyme replacement therapy (ERT) offers a method to supplement the deficient enzyme, potentially improving patient outcomes and quality of life. This article explores the mechanisms, benefits, challenges, and future prospects of Pompe disease enzyme replacement therapy. It also addresses patient eligibility, treatment protocols, and the impact on disease progression. Understanding these facets is essential for clinicians, patients, and caregivers involved in managing Pompe disease effectively. The following sections provide a detailed overview of the therapy, its clinical applications, and ongoing research.

Overview of Pompe Disease

Pompe disease, also known as glycogen storage disease type II, is a rare inherited disorder caused by mutations in the GAA gene. This gene is responsible for producing acid alpha-glucosidase, an enzyme critical for breaking down glycogen into glucose within lysosomes. When GAA is deficient or nonfunctional, glycogen accumulates abnormally in muscle cells, leading to cellular damage and impaired muscle function. The disease manifests in varying forms, ranging from the severe infantile-onset to the more slowly progressing late-onset Pompe disease.

Symptoms and Disease Progression

The clinical presentation of Pompe disease varies depending on the age of onset and residual enzyme activity. Infantile-onset Pompe disease typically presents within the first few months of life with profound muscle weakness, cardiomegaly, and respiratory failure. Late-onset Pompe disease often displays progressive skeletal muscle weakness, respiratory complications, and reduced mobility over years or decades. Without treatment, Pompe disease can result in significant morbidity and mortality, emphasizing the importance of early diagnosis and intervention.

Diagnosis Methods

Diagnosing Pompe disease involves a combination of clinical evaluation, biochemical assays, and genetic testing. Measurement of GAA enzyme activity in blood, muscle, or fibroblast samples serves as a primary diagnostic tool. Confirmatory genetic testing identifies pathogenic variants in the GAA gene. Additionally, muscle biopsies and imaging studies may assist in assessing disease severity and progression. Early and accurate diagnosis is critical for initiating timely enzyme replacement therapy and optimizing patient outcomes.

Mechanism of Enzyme Replacement Therapy

Enzyme replacement therapy for Pompe disease involves intravenous administration of recombinant human acid alpha-glucosidase to compensate for the deficient endogenous enzyme. This therapeutic approach aims to reduce glycogen accumulation within lysosomes, thereby improving muscle function and slowing disease progression. The recombinant enzyme is engineered to target muscle cells effectively, utilizing mannose-6-phosphate receptors for cellular uptake and lysosomal delivery.

Recombinant Human Acid Alpha-Glucosidase

The enzyme used in Pompe disease enzyme replacement therapy is produced through recombinant DNA technology, ensuring a consistent and safe supply of acid alpha-glucosidase. This synthetic enzyme mimics the natural human enzyme's activity, catalyzing the hydrolysis of glycogen into glucose inside lysosomes. The production process includes glycosylation patterns necessary for receptor recognition and cellular internalization.

Cellular Uptake and Lysosomal Targeting

Following intravenous infusion, the recombinant enzyme binds to mannose-6-phosphate receptors on the surface of target cells, particularly skeletal and cardiac muscle cells. This receptor-mediated endocytosis facilitates the

enzyme's transport into lysosomes, where it degrades accumulated glycogen. Efficient targeting and uptake are crucial for the therapeutic efficacy of enzyme replacement therapy in Pompe disease.

Clinical Application of Pompe Disease Enzyme Replacement Therapy

Since its approval, enzyme replacement therapy has become the standard of care for patients diagnosed with Pompe disease. The therapy is administered through regular intravenous infusions, typically every two weeks, under medical supervision. Clinical studies have demonstrated significant improvements in muscle strength, respiratory function, and survival rates in treated patients compared to untreated cohorts.

Infantile-Onset Pompe Disease Treatment

In infants diagnosed with Pompe disease, enzyme replacement therapy has been shown to markedly delay disease progression, improve cardiac function, and extend survival. Early initiation of therapy, preferably before significant symptom onset, is associated with better clinical outcomes, including motor development and respiratory independence. However, ongoing monitoring is essential to assess treatment response and address potential complications.

Late-Onset Pompe Disease Treatment

For patients with late-onset Pompe disease, enzyme replacement therapy helps stabilize or improve muscle strength and respiratory function. While the progression of muscle weakness may slow, the therapy does not completely reverse existing damage. Treatment adherence and long-term management are critical to maintaining patient quality of life and functional status.

Benefits and Limitations of Enzyme Replacement Therapy

Pompe disease enzyme replacement therapy offers substantial clinical benefits, yet it also presents certain limitations and challenges. Understanding these factors is vital for optimizing patient care and setting realistic treatment expectations.

Advantages of Enzyme Replacement Therapy

- Reduces glycogen accumulation in muscle cells, mitigating disease

progression.

- Improves cardiac and skeletal muscle function, particularly in infantile-onset patients.
- Enhances survival rates and quality of life across various disease forms.
- Provides a targeted therapeutic option addressing the underlying enzyme deficiency.

Challenges and Limitations

- High treatment cost and limited accessibility in certain regions.
- Potential immune responses leading to antibody formation against the recombinant enzyme.
- Variable efficacy depending on age at treatment initiation and disease severity.
- Need for lifelong biweekly infusions, which may affect patient compliance.

Patient Eligibility and Treatment Protocols

Determining patient eligibility for Pompe disease enzyme replacement therapy involves comprehensive diagnostic evaluation and clinical assessment. Treatment protocols are designed to maximize efficacy while monitoring for adverse effects.

Criteria for Initiation of Therapy

Patients with confirmed GAA deficiency and clinical symptoms consistent with Pompe disease are candidates for enzyme replacement therapy. Early diagnosis, particularly in newborns through screening programs, facilitates prompt treatment initiation. Genetic counseling and multidisciplinary evaluation support informed decision-making regarding therapy commencement.

Administration and Monitoring

Enzyme replacement therapy is administered intravenously, typically over 3 to

4 hours, every two weeks. During infusion, patients are monitored for infusion-related reactions, which can include allergic responses or respiratory symptoms. Regular follow-up evaluations assess muscle strength, pulmonary function, and antibody development. Adjustments to therapy may be necessary based on clinical response and tolerability.

Future Directions in Pompe Disease Treatment

Research continues to enhance the efficacy and accessibility of Pompe disease enzyme replacement therapy, alongside exploring novel therapeutic approaches. Advances in gene therapy, pharmacological chaperones, and next-generation enzymes hold promise for improved disease management.

Emerging Therapies and Innovations

Gene therapy aims to deliver functional copies of the GAA gene directly to patient cells, potentially providing a long-term cure by restoring endogenous enzyme production. Pharmacological chaperones are small molecules designed to stabilize the deficient enzyme, enhancing its activity. Additionally, improved formulations of recombinant enzymes seek to increase tissue targeting and reduce immune responses.

Personalized Medicine and Biomarker Development

Efforts are underway to identify biomarkers that predict treatment response and disease progression, enabling personalized therapeutic strategies. Tailoring enzyme replacement therapy based on individual genetic and clinical profiles may optimize outcomes and minimize adverse effects. Continued collaboration among researchers, clinicians, and patient communities is essential to advance these innovations.

Frequently Asked Questions

What is Pompe disease enzyme replacement therapy (ERT)?

Pompe disease enzyme replacement therapy (ERT) is a medical treatment that involves administering recombinant human acid alpha-glucosidase (rhGAA) to patients with Pompe disease to compensate for the deficient or malfunctioning enzyme responsible for breaking down glycogen in lysosomes.

How does enzyme replacement therapy work for Pompe disease?

ERT works by providing the missing or deficient enzyme acid alpha-glucosidase to the patient's body, which helps break down glycogen accumulation in muscle cells, improving muscle function and slowing disease progression.

Who is eligible for Pompe disease enzyme replacement therapy?

Patients diagnosed with Pompe disease, including both infantile-onset and late-onset forms, are typically eligible for ERT, although specific eligibility may depend on disease severity, age, and clinical guidelines.

What are the common side effects of Pompe disease enzyme replacement therapy?

Common side effects of ERT include infusion-related reactions such as fever, chills, rash, flushing, and sometimes allergic reactions, which are usually manageable with premedication and monitoring.

How effective is enzyme replacement therapy in treating Pompe disease?

ERT has been shown to improve survival rates, respiratory function, and motor skills in Pompe disease patients, especially when started early; however, it may not completely halt disease progression in all cases.

How often is enzyme replacement therapy administered for Pompe disease?

ERT for Pompe disease is typically administered via intravenous infusion every two weeks, with each infusion lasting several hours depending on the prescribed dosage and patient response.

Can enzyme replacement therapy reverse existing muscle damage in Pompe disease?

While ERT can reduce glycogen buildup and improve muscle function, it generally cannot fully reverse existing muscle damage, highlighting the importance of early diagnosis and treatment initiation.

Are there any new developments in Pompe disease enzyme replacement therapy?

Recent developments include improved formulations with better targeting to

muscle cells, longer-acting enzymes, and combination therapies designed to enhance the effectiveness and reduce immune responses to ERT.

What role does immune response play in Pompe disease enzyme replacement therapy?

Some patients may develop antibodies against the infused enzyme, which can reduce ERT effectiveness and increase infusion reactions; immune modulation strategies are sometimes used to manage this issue.

Is enzyme replacement therapy the only treatment option for Pompe disease?

ERT is currently the primary approved treatment for Pompe disease, but research is ongoing into gene therapy, chaperone therapy, and other approaches that may complement or provide alternatives to ERT in the future.

Additional Resources

1. *Pompe Disease and Enzyme Replacement Therapy: A Comprehensive Guide*
This book offers an in-depth exploration of Pompe disease, focusing on the development and application of enzyme replacement therapy (ERT). It covers the biochemical basis of the disease, clinical manifestations, and the therapeutic mechanisms of ERT. The text is designed for healthcare professionals, researchers, and students interested in lysosomal storage disorders.

2. *Advances in Enzyme Replacement Therapy for Pompe Disease*
Detailing the latest breakthroughs, this volume highlights recent advancements in ERT for Pompe disease. It includes clinical trial results, improvements in enzyme formulations, and strategies to enhance treatment efficacy. The book also discusses future directions and challenges in managing Pompe disease with ERT.

3. *Clinical Management of Pompe Disease: The Role of Enzyme Replacement Therapy*
Focusing on patient care, this book provides practical guidelines for diagnosing and managing Pompe disease using enzyme replacement therapy. It addresses dosage, administration protocols, and monitoring of treatment outcomes. Case studies illustrate real-world applications and patient responses to therapy.

4. *Enzyme Replacement Therapy in Lysosomal Storage Disorders: Pompe Disease Focus*
This text situates Pompe disease within the broader context of lysosomal storage disorders, emphasizing the role of ERT. It compares therapeutic approaches across different diseases and assesses the effectiveness of various enzymes. The book is a valuable resource for clinicians and

researchers working in metabolic disorders.

5. *Biotechnology and Enzyme Replacement Therapy for Pompe Disease*
Exploring the biotechnological aspects, this book delves into the production and engineering of enzymes used in Pompe disease therapy. It covers recombinant DNA technology, protein modification, and delivery systems that improve enzyme stability and uptake. The content is geared towards biotechnologists and pharmaceutical scientists.

6. *Patient Perspectives on Enzyme Replacement Therapy for Pompe Disease*
This unique volume compiles patient experiences and quality-of-life assessments related to ERT in Pompe disease. It highlights the psychological and social impacts of long-term treatment and the importance of patient-centered care. Healthcare providers can gain insights to better support their patients.

7. *Immunological Challenges in Enzyme Replacement Therapy for Pompe Disease*
Addressing a critical aspect of ERT, this book examines the immune responses elicited by enzyme infusions in Pompe patients. It discusses antibody development, allergic reactions, and strategies to mitigate immune complications. The text is essential for immunologists and clinicians managing ERT.

8. *Molecular Genetics and Therapeutic Innovations in Pompe Disease*
This book integrates genetic research with therapeutic advancements, including enzyme replacement therapy. It explains the genetic mutations causing Pompe disease and how this knowledge informs personalized treatment approaches. Emerging therapies and gene therapy prospects are also explored.

9. *Long-Term Outcomes of Enzyme Replacement Therapy in Pompe Disease*
Focusing on longitudinal studies, this book reviews the long-term efficacy and safety of ERT for Pompe disease patients. It analyzes survival rates, functional improvements, and potential adverse effects over extended treatment periods. The work provides valuable data for clinicians and policy makers in healthcare planning.

Pompe Disease Enzyme Replacement Therapy

pompe disease enzyme replacement therapy: Enzyme Replacement Therapy for Pompe Disease Ryan Jonathan William Burris, 2010 Pompe Disease is a rare genetic lysosomal storage disease resulting from mutations in the gene for acid alpha-glucosidase. Mutations in this gene cause a buildup of glycogen within lysosomes, leading to lysosomal engorgement and a disruption of

cellular processes. The heart and diaphragm are most often affected leading to death from cardiac or pulmonary failure. The only clinically available treatment methods are enzyme replacement therapy and nutritional and exercise therapy. Neither strategy completely resolves the syndrome, and enzyme replacement therapy is often too expensive for individuals. New treatment options for Pompe disease are needed. Guanidinylated neomycin (GNeo) is a novel molecular transporter which can target large bioactive molecules to the lysosome. If conjugated to acid alpha-glucosidase, GNeo may increase the efficacy of the currently available enzyme replacement therapy for Pompe disease by increasing the capacity of cells to take up the enzyme. In this thesis, the techniques required to demonstrate the efficacy of the GNeo molecular transporter are established. Methods for quantifying acid alpha-glucosidase presence and delivery to fibroblast lysosomes are demonstrated in vitro. A technique for inhibiting the mannose 6-phosphate (M6P) delivery of acid alpha-glucosidase to the endosomal pathway in vitro is described. Finally, a method for conjugating acid alpha-glucosidase to guanidinylated neomycin in order to increase the enzymes affinity for negatively charged glycosaminoglycans is developed.

pompe disease enzyme replacement therapy: Enzyme-replacement Therapy in Classic Infantile Pompe Disease: Long-term Outcome, Dosing and the Role of Antibodies , 2013

pompe disease enzyme replacement therapy: Children with Pompe Disease: Clinical Characteristics and Effects of Enzyme Replacement Therapy , 2014

pompe disease enzyme replacement therapy: Survival, Quality of Life and Effects of Enzyme Replacement Therapy in Adults with Pompe Disease: Outcomes of the IPA , 2013

pompe disease enzyme replacement therapy: *Newborn Screening for Pompe Disease* Wuh-Liang Hwu, Yin-Hsiu Chien, Raymond Wang, 2021-09-02 Pompe disease, also known as acid maltase deficiency or acid alpha-glucosidase deficiency, in its most severe form results in a rapidly progressive, neonatal-onset skeletal and cardiomyopathy, leading to early infantile death without treatment. The development of treatment with recombinant enzyme replacement therapy radically transformed the clinical trajectory of those affected, enabling long-term ventilator-free survival with resolution of cardiomyopathy. These positive clinical outcomes resulted in the implementation of newborn screening programs for Pompe disease across the world. This Special Issue highlights some of the experiences of Pompe screening programs worldwide and discusses public policy and ethical issues elicited by presymptomatic screening for Pompe disease.

pompe disease enzyme replacement therapy: *The McArdle Disease Handbook* Kathryn Elizabeth Birch, Ph.D., 2011-07-01 This handbook explains, in layman's terms, the cause, method of inheritance, history and current and future treatments of McArdle Disease (also known as Glycogen Storage Disease Type V). The handbook puts into plain English the published information relating to the scientific and medical research into McArdle Disease.

pompe disease enzyme replacement therapy: A Clinical Guide to Inherited Metabolic Diseases Joe T. R. Clarke, 2005-12-08 This user-friendly clinical handbook provides a clear and concise overview of how to go about recognizing and diagnosing inherited metabolic diseases. The reader is led through the diagnostic process from the identification of those features of an illness suggesting that it might be metabolic through the selection of appropriate laboratory investigation to a final diagnosis. The book is organized into chapters according to the most prominent presenting problem of patients with inherited metabolic diseases: neurologic, hepatic, cardiac, metabolic acidosis, dysmorphism, and acute catastrophic illness in the newborn. It also includes chapters on general principles, laboratory investigation, neonatal screening, and the principles of treatment. This new edition includes much greater depth on mitochondrial disease and congenital disorders of glycosylation. The chapters on neurological syndrome and newborn screening are greatly expanded, as are those on laboratory investigation and treatment, to take account of the very latest technological developments.

pompe disease enzyme replacement therapy: Neurometabolic Hereditary Diseases of Adults Alessandro P. Burlina, 2018-06-04 This practical book describes only neurometabolic hereditary diseases which have a specific treatment and encourages the general neurologist to think

of the most common neurometabolic hereditary diseases, which he might have seen and never considered in the differential diagnosis. Information regarding how to deal with diseases with special therapy is provided (i.e. enzymatic replacement therapy in Fabry disease and Pompe disease), as is information on diseases which are not easily recognized (i.e. Niemann-Pick disease type C), and diseases with clinical features mimicking other common neurodegenrative diseases (i.e. Wilson's disease). Neurometabolic Hereditary Diseases is written with a clinical focus for adult neurologists working in general hospitals.

pompe disease enzyme replacement therapy: Stem Cell Therapy in Lysosomal Storage Diseases Jaap Jan Boelens, Robert Wynn, 2013-10-10 Stem Cell therapy for lysosomal diseases (LSDs) is developing rapidly. This volume discusses the history, current practice and future perspectives of stem cells in inborn errors of metabolism (IEM) and provides an international perspective on progress, limitations, and future directions (e.g. gene therapy, iPS, ES) in the field. Beginning with an overview of these diseases, the book covers the breadth of this topic from treatment options, bone marrow transplantation, and alternative treatment options, through long-term outcomes and future perspectives.

pompe disease enzyme replacement therapy: Myopathies, An Issue of Neurologic Clinics Mazen Dimachkie, 2014-07-23 Congential myopathies, Muscular dystropies, Glycogen storage diseases of muscle, and Idiopathic and Inflammatory myopathies are presented in this volume of Neurologic Clinics. Topics include: Muscle channelopathies; Pompe disease; Congenital myopathies and muscular dystrophies; Duchenne and Becker muscular dystrophies; Distal myopathies; Limb-girdle muscular dystrophy; Fascioscapulomuneral muscular dystrophy; Myotonic dystrophy; Metabolic and mitochondrial myopathies; Sporadic inclusion body myositis; Toxic myopathies; Idiopathic Inflammatory myopathies; Approach to muscle disease.

pompe disease enzyme replacement therapy: *Muscle Gene Therapy* Dongsheng Duan, Jerry R. Mendell, 2019-03-30 About 7 million people worldwide are suffering from various inherited neuromuscular diseases. Gene therapy brings the hope of treating these diseases at their genetic roots. Muscle Gene Therapy is the only book dedicated to this topic. The first edition was published in 2010 when the field was just about to enter its prime time. The progress made since then has been unprecedented. The number of diseases that have been targeted by gene therapy has increased tremendously. The gene therapy toolbox is expanded greatly with many creative novel strategies (such as genome editing and therapy with disease-modifying genes). Most importantly, clinical benefits have begun to emerge in human patients. To reflect rapid advances in the field, we have compiled the second edition of Muscle Gene Therapy with contributions from experts that have conducted gene therapy studies either in animal models and/or in human patients. The new edition offers a much needed, up-to-date overview and perspective on the foundation and current status of neuromuscular disease gene therapy. It provides a framework to the development and regulatory approval of muscle gene therapy drugs in the upcoming years. This book is a must-have for anyone who is interested in neuromuscular disease gene therapy including those in the research arena (established investigators and trainees in the fields of clinical practice, veterinary medicine and basic biomedical sciences), funding and regulatory agencies, and patient community.

pompe disease enzyme replacement therapy: Pompe's Disease: New Insights for the Healthcare Professional: 2012 Edition , 2012-12-10 Pompe's Disease: New Insights for the Healthcare Professional: 2012 Edition is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about Pompe's Disease in a compact format. The editors have built Pompe's Disease: New Insights for the Healthcare Professional: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Pompe's Disease in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Pompe's Disease: New Insights for the Healthcare Professional: 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from

us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

pompe disease enzyme replacement therapy: Atlas of Inherited Metabolic Diseases William L Nyhan, Georg F Hoffmann, 2020-07-14 In a field where even experts may find that years have elapsed since they last encountered a child with a given disorder, it is essential for the clinician to have a comprehensive source of practical and highly illustrated information covering the whole spectrum of metabolic disease to refer to. The content is divided into sections of related disorders, including disorders of amino acid metabolism, lipid storage disorders, and mitochondrial diseases for ease of reference, with an introductory outline where appropriate summarizing the biochemical features and general management issues. Within the sections, each chapter deals with an individual disease, opening with a useful summary of major phenotypic expression including clear and helpful biochemical pathways, identifying for the reader exactly where the defect occurs. Throughout the book, plentiful photographs, often showing extremely rare disorders, are an invaluable aid to diagnosis. Key Features • Fully updated to incorporate all new developments in the field • Brand new chapters cover methylmalonic aciduria of ACSF3 deficiency, branched chain keto acid dehydrogenase deficiency, serine deficiencies, purine nucleoside phosphorylase deficiency, antiquitin deficiency, and others • Excellent and detailed clinical descriptions, with numerous valuable hints and suggestions for management • Helpful explanatory algorithms and decision trees, and high-quality illustrative material including biochemical pathways and an unrivaled photographic collection, which enhance clinical applicability The fourth edition of this highly regarded book, authored by two of the foremost authorities in pediatric metabolic medicine, continues to provide incomparable insight into the problems associated with metabolic diseases and remains invaluable to pediatricians, geneticists, and general clinicians worldwide.

pompe disease enzyme replacement therapy: Rogers' Textbook of Pediatric Intensive Care Donald H. Shaffner, David G. Nichols, 2015-07-29 Now in vibrant full color throughout, Rogers’ Textbook of Pediatric Intensive Care, 5th Edition, continues its tradition of excellence as the gold standard in the field. For more than 25 years, readers have turned to this comprehensive resource for clear explanations of both the principles underlying pediatric critical care disease and trauma as well as how these principles are applied in clinical practice. In the 5th Edition, more than 250 global contributors bring you completely up to date on today’s understanding, treatments, technologies, and outcomes regarding critical illness in children.

pompe disease enzyme replacement therapy: Pathophysiological Mechanisms of Sarcopenia in Aging and in Muscular Dystrophy: A Translational Approach Luciano Merlini, Paolo Bonaldo, Emanuele Marzetti, 2016-01-18 Loss of muscle mass and increased fibrosis characterize both sarcopenia of aging and muscular dystrophy. Research is increasingly showing that these two conditions also share several pathophysiological mechanisms, including mitochondrial dysfunction, increased apoptosis, abnormal modulation of autophagy, decline in satellite cells, increased generation of reactive oxygen species, and abnormal regulation of signaling and stress response pathways. This Research Topic will cover several mechanisms involved in aging and dystrophic sarcopenia and explore the therapeutic potential of various strategies for intervention.

pompe disease enzyme replacement therapy: Glycogen Storage Disease: New Insights for the Healthcare Professional: 2013 Edition , 2013-07-22 Glycogen Storage Disease: New Insights for the Healthcare Professional: 2013 Edition is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about Additional Research in a compact format. The editors have built Glycogen Storage Disease: New Insights for the Healthcare Professional: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Additional Research in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Glycogen Storage Disease: New Insights for the Healthcare Professional: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors

at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

pompe disease enzyme replacement therapy: New-opathies Errol C. Friedberg, 2012 This book presents new insights into the etiology and pathogenesis of systemic diseases recently discovered to be due to specific defects in molecular assemblies, organelles, or other subcellular structures. This new information, of great importance to medical students, physicians, and basic scientists, has not been incorporated into major medical textbooks.The volume will be an important resource for medical or graduate students, investigators and physicians, as it covers major new insights into diverse diseases and concepts missing from pathology textbooks. Each of the eight chapters in the book is written by a leader in the field.

pompe disease enzyme replacement therapy: *Inherited White Matter Disorders and Their Mimics* , 2024-09-23 Inherited White Matter Disorders and Their Mimics, Volume 204 discusses where imaging abnormalities and pathology lie predominantly in the CNS white matter. Many acquired causes, such as multiple sclerosis, are readily diagnosed and familiar to the majority of neurologists. However, less common acquired causes and genetic disorders (the leukodystrophies and genetic leukoencephalopathies) often present a diagnostic challenge. The evaluation of patients with White matter disorders (WMDs) has evolved enormously in recent decades, due to advances in genetics, radiology, and the development of treatments for specific disorders. This book brings together WMD research, spanning basic science, molecular genetics, and clinical and radiological phenotyping.This volume presents both common WMDs and rare disorders according to their presentations or pathophysiology. Chapters lay out the clinical and radiological presentation of the disorder, followed by genetics and diagnostics, and finally discussion of pathophysiology and treatment. Chapter contain imaging, clinical pearls to diagnosis, and reference tables for genotype-phenotype correlation. For diagnostic work-up, easy to read algorithms are presented as well as clear guidance on indications for treatment, where applicable. - Includes common and rare white matter disorders (WMDs) - Summarizes advances in genetics, radiology, and treatments for WMDs - Provides clinical and radiological phenotyping - Contains imaging, diagnostic algorithms, and guidance on treatment

pompe disease enzyme replacement therapy: JIMD Reports - Case and Research Reports, 2012/5 Johannes Zschocke, K Michael Gibson, Garry Brown, Eva Morava, Verena Peters, 2012-10-02 JIMD Reports publishes case and short research reports in the area of inherited metabolic disorders. Case reports highlight some unusual or previously unrecorded feature relevant to the disorder, or serve as an important reminder of clinical or biochemical features of a Mendelian disorder.

pompe disease enzyme replacement therapy: JIMD Reports, Volume 23 Johannes Zschocke, Matthias Baumgartner, Eva Morava, Marc Patterson, Shamima Rahman, Verena Peters, 2015-06-29 JIMD Reports publishes case and short research reports in the area of inherited metabolic disorders. Case reports highlight some unusual or previously unrecorded feature relevant to the disorder, or serve as an important reminder of clinical or biochemical features of a Mendelian disorder.

Related to pompe disease enzyme replacement therapy

Pompe Disease: a Clinical, Diagnostic, and Therapeutic Overview This review summarizes the clinical presentation and provides an update on the current strategies for diagnosis of Pompe disease. We will review the available treatment options. We examine

MDA-MCDA 17001 Flash Card DMD v9 Pompe is classified as a metabolic muscle disorder, one of a group of diseases that interferes with processing and storage of complex sugars (carbohydrates). The build-up of sugar molecules in

What is Pompe disease? | Pompe Disease News Pompe disease is a rare genetic disorder marked by the buildup inside cells of the sugar molecule glycogen, which damages organs and tissues

Glycogen Storage Disease, Type II (Pompe Disease) - Learn more about glycogen storage disease, type II (Pompe Disease). Find out about newborn screening for Pompe Disease, signs and symptoms, what happens next, and

Lysosomal acid alpha-glucosidase deficiency (Pompe disease - UpToDate Comprehensive guide on lysosomal acid alpha-glucosidase deficiency (Pompe disease), covering its clinical manifestations, diagnosis, and management strategies

Pompe Disease News Home | Pompe Disease News Get the latest news on Pompe disease, its causes, symptoms, diagnosis, and treatments. Hear patient and caregiver voices from our growing Pompe community

Pompe Disease | Nemours KidsHealth Pompe disease is a rare genetic condition that causes muscle weakness that gets worse over time. It can have a serious effect on many of the body's systems. Pompe disease is also called

What is Pompe Disease? What are the symptoms of Pompe Pompe disease is an inherited disorder characterized by muscle weakness, respiratory insufficiency and, in some forms, enlargement of the heart.1 It involves deficiency of the

Pompe | Baby's First Test | Newborn Screening | Baby Health Pompe is an inherited condition that affects many different parts of the body. It is considered a lysosomal storage disorder because people with Pompe have lysosomes (the recycling center

Pompe Disease | Glycogen Storage Disease Type II | Duke Health Pompe disease is a genetic disease that occurs when a specific enzyme (acid alpha-glucosidase) is absent or the body doesn't produce enough. This results in the buildup of a complex sugar

Pompe Consortium | Pompe Disease Ecosystem & Database The Pompe Consortium embodies the intersection of the Pompe Disease ecosystem—patients, academia, industry, advocates, researchers, regulators—with the explicit purpose to accelerate

Pompe Disease - GeneReviews® - NCBI Bookshelf Pompe disease can be classified by age of onset, organ involvement, severity, and rate of progression into infantile-onset Pompe disease (IOPD) (i.e., individuals with onset

Pompe Disease - Stanford Medicine Pompe disease, (also known as Glycogen Storage Disease type II), is a type of lysosomal storage disease, meaning there is an issue in how parts of the cell (lysosomes) break down certain

About Pompe disease - Astellas Gene Therapies Pompe disease Pompe disease (also known as glycogen storage disease type II or acid maltase deficiency) is a rare, genetic, metabolic disorder. Pompe disease is caused by

About Pompe Disease - United Pompe Foundation Pompe Disease A progressive, multisystemic, debilitation, and often fatal muscular disease Single disease continuum presenting with variable rates of progression Presentation ranges

How is Pompe disease diagnosed? | Pompe Disease News A diagnosis of Pompe disease typically requires testing the activity of the acid alpha-glucosidase enzyme as a first-line method. This enzyme normally breaks down a

How Is Pompe Disease Treated? - WebMD To get the best care for Pompe disease, you need treatment from a team of health care professionals. Here’s what treatment for you or your child may include

Pompe Disease - UF Health Pompe Disease Registry The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the

Pompe Disease | Lurie Children's A rare genetic disease of the heart and skeletal muscles caused by a lack alpha-glucosidase which results in the build-up of glycogen, disabling heart and skeletal muscles

NEXVIAZYME® (avalglucosidase alfa-ngpt) | Late-Onset Pompe Learn about NEXVIAZYME® (avalglucosidase alfa-ngpt), an M6P-enriched enzyme replacement therapy for late-onset Pompe disease (LOPD). Please see Important Safety Information,

Pompe Disease An overview of Pompe disease, including pathophysiology, disease spectrum, challenges in diagnosis, and testing and disease registry resources for providers

Home - AMDA Pompe 5 days ago This past May, our hearts broke twice. Within just two weeks, the Pompe community said goodbye to two extraordinary advocates: Maryze Schoneveld van der Linde with the IPA,

You have Pompe disease, it doesn't have you Welcome to Pompeandyou.com, an educational community that provides information and resources to help you along your journey with Pompe disease

Pompe Disease - Lysosomal Center Pompe disease is a Lysosomal disorder caused by the accumulation of a complex sugar called glycogen in muscles and other organs and tissues. The lack of acid alpha-glucosidase, the

Management of Pompe disease alongside and beyond ERT: a Pompe disease is a lysosomal storage disorder that primarily affects muscles, and its natural history has been transformed over the past 20 years by therapies designed to restore the

Pompe Disease Awareness: Symptoms, Causes, and Treatment Learn about Pompe disease—a rare genetic disorder affecting the heart and skeletal muscles. Explore symptoms, causes, and treatment options

Pompe disease treatment options | Pompe Disease News There is no cure for Pompe disease, but treatments — including Lumizyme, Nexviazyme, and Pombiliti + Opfolda — can slow disease progression

The Physician’s Guide to Pompe Disea What is Pompe Disease? Pompe disease is an autosomal recessively inherited metabolic disorder that affects one of more than 40 lysosomal enzymes. Patients with Pompe disease

Home - AMDA Pompe The Acid Maltase Deficiency Association formed to assist in funding research and to promote public awareness of Acid Maltase Deficiency, also known as Pompe’s Disease

Symptoms - International Pompe Association Pompe disease is a rare genetic disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA), leading to an abnormal accumulation of glycogen in various tissues of the

Pompe Disease - Metabolic Support UK Pompe Disease is caused by a problem in the GAA gene. This gene provides instructions for the enzyme acid alpha-glucosidase (acid maltase) which breaks down glycogen. This process is

Pompe Disease - Acid Maltase Deficiency | Rare Disease Advisor Pompe disease, also known as acid maltase deficiency or glycogen storage disease type II, is a rare genetic disorder characterized by a deficiency or absence of the lysosomal acid alpha

Updates in Pompe Disease: Overview and Emerging Overview1-3 Pompe disease (aka glycogen storage disease type II [GSD II] or acid maltase deficiency [AMD]) is a rare autosomal recessive genetic disorder1,2

Pompe Disease | Mount Sinai - New York Pompe disease is caused by mutations in the GAA gene. Mutations in the GAA gene result in the deficiency of an enzyme, acid alpha-glucosidase, that is necessary for the breakdown of a

Pompe Disease | LSDSS India Pompe disease is an inherited disorder caused by the buildup of a complex sugar called glycogen in the body’s cells. The accumulation of glycogen in certain organs and tissues, especially

Pompe Disease - Causes, Symptoms, Diagnosis, and Treatment Definition Pompe Disease is a genetic disorder caused by the deficiency of an enzyme called acid alpha-glucosidase (GAA). This enzyme is essential for breaking down

Pompe Warrior Foundation The mission of the Pompe Warrior Foundation is to promote research, educate, and empower individuals and families affected by Pompe Disease and other Lysosomal Storage Diseases.

Pompe Disease | UPMC Children’s Hospital of Pittsburgh Pompe disease is a rare genetic

condition that weakens a child’s heart and muscles. Prompt detection is vital. Find expert care at UPMC Children’s-Pittsburgh

Glycogen storage disease type II - Glycogen storage disease type II, also known as Pompe disease or acid maltase deficiency disease, is an inherited lysosomal storage disorder characterized by abnormal

Newborn Screening - Pompe Disease - EveryLife Foundation for Rare Diseases General Information Pompe disease is a rare, progressive, and life-threatening genetic lysosomal storage disorder that affects many parts of the body including the muscles, heart, and central

Pompe Disease Diet and Nutrition - Rare Disease Advisor Pompe disease, also referred to as glycogen storage disease type II, is a genetic myopathy that results from a deficiency of the enzyme acid alpha-glucosidase. As a result of the deficiency,

Pompe Disease - Boston Children's Hospital Pompe disease is caused by a genetic mutation that causes a buildup of complex sugars in the body’s tissues. This buildup makes it difficult for children with the disease to function normally.

What Is Pompe Disease? Symptoms, Causes, Diagnosis, and Pompe disease is a rare, inherited genetic disorder in which the body cannot break down glycogen, leading to muscle weakness and an enlarged heart

Pompe Disease - Practical Neurology Pompe disease is a rare metabolic myopathy caused by a deficiency of the alpha-glucosidase (GAA) enzyme, which is involved the breakdown of glycogen. The GAA deficiency

Gene Therapy for Infantile-Onset Pompe’s Disease Pompe’s disease is a lysosomal storage disorder that manifests as a metabolic myopathy and is almost invariably associated with severe and progressive physical disability

Pompe Disease | ASGCT - American Society of Gene & Cell Therapy Pompe disease occurs when the genes that instruct our cells to create the GAA enzyme are faulty. The GAA enzyme’s job is to break down complex molecules like glycogen,

A Beacon of Hope Found for the Future of Pompe Disease Bruce is an advocate for Pompe disease. Confined to a wheelchair with complete paralysis, and being told he would never walk again, set Bruce in literal motion to engage in a

Pompe Disease Pathophysiology - Rare Disease Advisor Pompe disease is a rare autosomal recessive disorder also known as Type II glycogen storage disease (GSDII). 1,2 This is a severe multisystemic metabolic disorder that is often fatal and

Pompe Disease - BrainFacts Pompe Disease Pompe disease is a rare (estimated at 1 in every 40,000 births), inherited and often fatal disorder that disables the heart and skeletal muscles. It is caused by mutations in a

Pompe disease symptoms: Early signs to look out for – Pompe Pompe disease symptoms can vary, depending on age of onset and disease type. Common symptoms include muscle weakness and breathing issues

Pompe Disease: a Clinical, Diagnostic, and Therapeutic Overview This review summarizes the clinical presentation and provides an update on the current strategies for diagnosis of Pompe disease. We will review the available treatment options. We examine

MDA-MCDA 17001 Flash Card DMD v9 Pompe is classified as a metabolic muscle disorder, one of a group of diseases that interferes with processing and storage of complex sugars (carbohydrates). The build-up of sugar molecules in

What is Pompe disease? | Pompe Disease News Pompe disease is a rare genetic disorder marked by the buildup inside cells of the sugar molecule glycogen, which damages organs and tissues

Glycogen Storage Disease, Type II (Pompe Disease) - Learn more about glycogen storage disease, type II (Pompe Disease). Find out about newborn screening for Pompe Disease, signs and symptoms, what happens next, and

Lysosomal acid alpha-glucosidase deficiency (Pompe disease - UpToDate Comprehensive

guide on lysosomal acid alpha-glucosidase deficiency (Pompe disease), covering its clinical manifestations, diagnosis, and management strategies

Pompe Disease News Home | Pompe Disease News Get the latest news on Pompe disease, its causes, symptoms, diagnosis, and treatments. Hear patient and caregiver voices from our growing Pompe community

Pompe Disease | Nemours KidsHealth Pompe disease is a rare genetic condition that causes muscle weakness that gets worse over time. It can have a serious effect on many of the body's systems. Pompe disease is also called

What is Pompe Disease? What are the symptoms of Pompe Pompe disease is an inherited disorder characterized by muscle weakness, respiratory insufficiency and, in some forms, enlargement of the heart.1 It involves deficiency of the

Pompe | Baby's First Test | Newborn Screening | Baby Health Pompe is an inherited condition that affects many different parts of the body. It is considered a lysosomal storage disorder because people with Pompe have lysosomes (the recycling center

Pompe Disease | Glycogen Storage Disease Type II | Duke Health Pompe disease is a genetic disease that occurs when a specific enzyme (acid alpha-glucosidase) is absent or the body doesn't produce enough. This results in the buildup of a complex sugar

Pompe Consortium | Pompe Disease Ecosystem & Database The Pompe Consortium embodies the intersection of the Pompe Disease ecosystem—patients, academia, industry, advocates, researchers, regulators—with the explicit purpose to accelerate

Pompe Disease - GeneReviews® - NCBI Bookshelf Pompe disease can be classified by age of onset, organ involvement, severity, and rate of progression into infantile-onset Pompe disease (IOPD) (i.e., individuals with onset

Pompe Disease - Stanford Medicine Pompe disease, (also known as Glycogen Storage Disease type II), is a type of lysosomal storage disease, meaning there is an issue in how parts of the cell (lysosomes) break down certain

About Pompe disease - Astellas Gene Therapies Pompe disease Pompe disease (also known as glycogen storage disease type II or acid maltase deficiency) is a rare, genetic, metabolic disorder. Pompe disease is caused by

About Pompe Disease - United Pompe Foundation Pompe Disease A progressive, multisystemic, debilitation, and often fatal muscular disease Single disease continuum presenting with variable rates of progression Presentation ranges

How is Pompe disease diagnosed? | Pompe Disease News A diagnosis of Pompe disease typically requires testing the activity of the acid alpha-glucosidase enzyme as a first-line method. This enzyme normally breaks down a

How Is Pompe Disease Treated? - WebMD To get the best care for Pompe disease, you need treatment from a team of health care professionals. Here’s what treatment for you or your child may include

Pompe Disease - UF Health Pompe Disease Registry The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the

Pompe Disease | Lurie Children's A rare genetic disease of the heart and skeletal muscles caused by a lack alpha-glucosidase which results in the build-up of glycogen, disabling heart and skeletal muscles

NEXVIAZYME® (avalglucosidase alfa-ngpt) | Late-Onset Pompe Learn about NEXVIAZYME® (avalglucosidase alfa-ngpt), an M6P-enriched enzyme replacement therapy for late-onset Pompe disease (LOPD). Please see Important Safety Information,

Pompe Disease An overview of Pompe disease, including pathophysiology, disease spectrum, challenges in diagnosis, and testing and disease registry resources for providers

Home - AMDA Pompe 5 days ago This past May, our hearts broke twice. Within just two weeks, the Pompe community said goodbye to two extraordinary advocates: Maryze Schoneveld van der

Linde with the IPA,

You have Pompe disease, it doesn't have you Welcome to Pompeandyou.com, an educational community that provides information and resources to help you along your journey with Pompe disease

Pompe Disease - Lysosomal Center Pompe disease is a Lysosomal disorder caused by the accumulation of a complex sugar called glycogen in muscles and other organs and tissues. The lack of acid alpha-glucosidase, the

Management of Pompe disease alongside and beyond ERT: a Pompe disease is a lysosomal storage disorder that primarily affects muscles, and its natural history has been transformed over the past 20 years by therapies designed to restore the

Pompe Disease Awareness: Symptoms, Causes, and Treatment Learn about Pompe disease—a rare genetic disorder affecting the heart and skeletal muscles. Explore symptoms, causes, and treatment options

Pompe disease treatment options | Pompe Disease News There is no cure for Pompe disease, but treatments — including Lumizyme, Nexviazyme, and Pombiliti + Opfolda — can slow disease progression

The Physician's Guide to Pompe Disea What is Pompe Disease? Pompe disease is an autosomal recessively inherited metabolic disorder that affects one of more than 40 lysosomal enzymes. Patients with Pompe disease

Home - AMDA Pompe The Acid Maltase Deficiency Association formed to assist in funding research and to promote public awareness of Acid Maltase Deficiency, also known as Pompe's Disease

Symptoms - International Pompe Association Pompe disease is a rare genetic disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA), leading to an abnormal accumulation of glycogen in various tissues of the

Pompe Disease - Metabolic Support UK Pompe Disease is caused by a problem in the GAA gene. This gene provides instructions for the enzyme acid alpha-glucosidase (acid maltase) which breaks down glycogen. This process is

Pompe Disease - Acid Maltase Deficiency | Rare Disease Advisor Pompe disease, also known as acid maltase deficiency or glycogen storage disease type II, is a rare genetic disorder characterized by a deficiency or absence of the lysosomal acid alpha

Updates in Pompe Disease: Overview and Emerging Overview1-3 Pompe disease (aka glycogen storage disease type II [GSD II] or acid maltase deficiency [AMD]) is a rare autosomal recessive genetic disorder1,2

Pompe Disease | Mount Sinai - New York Pompe disease is caused by mutations in the GAA gene. Mutations in the GAA gene result in the deficiency of an enzyme, acid alpha-glucosidase, that is necessary for the breakdown of a

Pompe Disease | LSDSS India Pompe disease is an inherited disorder caused by the buildup of a complex sugar called glycogen in the body's cells. The accumulation of glycogen in certain organs and tissues, especially

Pompe Disease - Causes, Symptoms, Diagnosis, and Treatment Definition Pompe Disease is a genetic disorder caused by the deficiency of an enzyme called acid alpha-glucosidase (GAA). This enzyme is essential for breaking down

Pompe Warrior Foundation The mission of the Pompe Warrior Foundation is to promote research, educate, and empower individuals and families affected by Pompe Disease and other Lysosomal Storage Diseases.

Pompe Disease | UPMC Children's Hospital of Pittsburgh Pompe disease is a rare genetic condition that weakens a child's heart and muscles. Prompt detection is vital. Find expert care at UPMC Children's-Pittsburgh

Glycogen storage disease type II - Glycogen storage disease type II, also known as Pompe disease or acid maltase deficiency disease, is an inherited lysosomal storage disorder characterized

by abnormal

Newborn Screening - Pompe Disease - EveryLife Foundation for Rare Diseases General Information Pompe disease is a rare, progressive, and life-threatening genetic lysosomal storage disorder that affects many parts of the body including the muscles, heart, and central

Pompe Disease Diet and Nutrition - Rare Disease Advisor Pompe disease, also referred to as glycogen storage disease type II, is a genetic myopathy that results from a deficiency of the enzyme acid alpha-glucosidase. As a result of the deficiency,

Pompe Disease - Boston Children's Hospital Pompe disease is caused by a genetic mutation that causes a buildup of complex sugars in the body's tissues. This buildup makes it difficult for children with the disease to function normally.

What Is Pompe Disease? Symptoms, Causes, Diagnosis, and Pompe disease is a rare, inherited genetic disorder in which the body cannot break down glycogen, leading to muscle weakness and an enlarged heart

Pompe Disease - Practical Neurology Pompe disease is a rare metabolic myopathy caused by a deficiency of the alpha-glucosidase (GAA) enzyme, which is involved the breakdown of glycogen. The GAA deficiency

Gene Therapy for Infantile-Onset Pompe's Disease Pompe's disease is a lysosomal storage disorder that manifests as a metabolic myopathy and is almost invariably associated with severe and progressive physical disability

Pompe Disease | ASGCT - American Society of Gene & Cell Therapy Pompe disease occurs when the genes that instruct our cells to create the GAA enzyme are faulty. The GAA enzyme's job is to break down complex molecules like glycogen,

A Beacon of Hope Found for the Future of Pompe Disease Bruce is an advocate for Pompe disease. Confined to a wheelchair with complete paralysis, and being told he would never walk again, set Bruce in literal motion to engage in a

Pompe Disease Pathophysiology - Rare Disease Advisor Pompe disease is a rare autosomal recessive disorder also known as Type II glycogen storage disease (GSDII). 1,2 This is a severe multisystemic metabolic disorder that is often fatal and

Pompe Disease - BrainFacts Pompe Disease Pompe disease is a rare (estimated at 1 in every 40,000 births), inherited and often fatal disorder that disables the heart and skeletal muscles. It is caused by mutations in a

Pompe disease symptoms: Early signs to look out for – Pompe Pompe disease symptoms can vary, depending on age of onset and disease type. Common symptoms include muscle weakness and breathing issues

Pompe Disease: a Clinical, Diagnostic, and Therapeutic Overview This review summarizes the clinical presentation and provides an update on the current strategies for diagnosis of Pompe disease. We will review the available treatment options. We examine

MDA-MCDA 17001 Flash Card DMD v9 Pompe is classified as a metabolic muscle disorder, one of a group of diseases that interferes with processing and storage of complex sugars (carbohydrates). The build-up of sugar molecules in

What is Pompe disease? | Pompe Disease News Pompe disease is a rare genetic disorder marked by the buildup inside cells of the sugar molecule glycogen, which damages organs and tissues

Glycogen Storage Disease, Type II (Pompe Disease) - Learn more about glycogen storage disease, type II (Pompe Disease). Find out about newborn screening for Pompe Disease, signs and symptoms, what happens next, and

Lysosomal acid alpha-glucosidase deficiency (Pompe disease - UpToDate Comprehensive guide on lysosomal acid alpha-glucosidase deficiency (Pompe disease), covering its clinical manifestations, diagnosis, and management strategies

Pompe Disease News Home | Pompe Disease News Get the latest news on Pompe disease, its causes, symptoms, diagnosis, and treatments. Hear patient and caregiver voices from our growing

Pompe community

Pompe Disease | Nemours KidsHealth Pompe disease is a rare genetic condition that causes muscle weakness that gets worse over time. It can have a serious effect on many of the body's systems. Pompe disease is also called

What is Pompe Disease? What are the symptoms of Pompe Pompe disease is an inherited disorder characterized by muscle weakness, respiratory insufficiency and, in some forms, enlargement of the heart.1 It involves deficiency of the

Pompe | Baby's First Test | Newborn Screening | Baby Health Pompe is an inherited condition that affects many different parts of the body. It is considered a lysosomal storage disorder because people with Pompe have lysosomes (the recycling center

Pompe Disease | Glycogen Storage Disease Type II | Duke Health Pompe disease is a genetic disease that occurs when a specific enzyme (acid alpha-glucosidase) is absent or the body doesn't produce enough. This results in the buildup of a complex sugar

Pompe Consortium | Pompe Disease Ecosystem & Database The Pompe Consortium embodies the intersection of the Pompe Disease ecosystem—patients, academia, industry, advocates, researchers, regulators—with the explicit purpose to accelerate

Pompe Disease - GeneReviews® - NCBI Bookshelf Pompe disease can be classified by age of onset, organ involvement, severity, and rate of progression into infantile-onset Pompe disease (IOPD) (i.e., individuals with onset

Pompe Disease - Stanford Medicine Pompe disease, (also known as Glycogen Storage Disease type II), is a type of lysosomal storage disease, meaning there is an issue in how parts of the cell (lysosomes) break down certain

About Pompe disease - Astellas Gene Therapies Pompe disease Pompe disease (also known as glycogen storage disease type II or acid maltase deficiency) is a rare, genetic, metabolic disorder. Pompe disease is caused by

About Pompe Disease - United Pompe Foundation Pompe Disease A progressive, multisystemic, debilitation, and often fatal muscular disease Single disease continuum presenting with variable rates of progression Presentation ranges

How is Pompe disease diagnosed? | Pompe Disease News A diagnosis of Pompe disease typically requires testing the activity of the acid alpha-glucosidase enzyme as a first-line method. This enzyme normally breaks down a

How Is Pompe Disease Treated? - WebMD To get the best care for Pompe disease, you need treatment from a team of health care professionals. Here’s what treatment for you or your child may include

Pompe Disease - UF Health Pompe Disease Registry The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the

Pompe Disease | Lurie Children's A rare genetic disease of the heart and skeletal muscles caused by a lack alpha-glucosidase which results in the build-up of glycogen, disabling heart and skeletal muscles

NEXVIAZYME® (avalglucosidase alfa-ngpt) | Late-Onset Pompe Learn about NEXVIAZYME® (avalglucosidase alfa-ngpt), an M6P-enriched enzyme replacement therapy for late-onset Pompe disease (LOPD). Please see Important Safety Information,

Pompe Disease An overview of Pompe disease, including pathophysiology, disease spectrum, challenges in diagnosis, and testing and disease registry resources for providers

Home - AMDA Pompe 5 days ago This past May, our hearts broke twice. Within just two weeks, the Pompe community said goodbye to two extraordinary advocates: Maryze Schoneveld van der Linde with the IPA,

You have Pompe disease, it doesn't have you Welcome to Pompeandyou.com, an educational community that provides information and resources to help you along your journey with Pompe disease

Pompe Disease - Lysosomal Center Pompe disease is a Lysosomal disorder caused by the accumulation of a complex sugar called glycogen in muscles and other organs and tissues. The lack of acid alpha-glucosidase, the

Management of Pompe disease alongside and beyond ERT: a Pompe disease is a lysosomal storage disorder that primarily affects muscles, and its natural history has been transformed over the past 20 years by therapies designed to restore the

Pompe Disease Awareness: Symptoms, Causes, and Treatment Learn about Pompe disease—a rare genetic disorder affecting the heart and skeletal muscles. Explore symptoms, causes, and treatment options

Pompe disease treatment options | Pompe Disease News There is no cure for Pompe disease, but treatments — including Lumizyme, Nexviazyme, and Pombiliti + Opfolda — can slow disease progression

The Physician's Guide to Pompe Disea What is Pompe Disease? Pompe disease is an autosomal recessively inherited metabolic disorder that affects one of more than 40 lysosomal enzymes. Patients with Pompe disease

Home - AMDA Pompe The Acid Maltase Deficiency Association formed to assist in funding research and to promote public awareness of Acid Maltase Deficiency, also known as Pompe's Disease

Symptoms - International Pompe Association Pompe disease is a rare genetic disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA), leading to an abnormal accumulation of glycogen in various tissues of the

Pompe Disease - Metabolic Support UK Pompe Disease is caused by a problem in the GAA gene. This gene provides instructions for the enzyme acid alpha-glucosidase (acid maltase) which breaks down glycogen. This process is

Pompe Disease - Acid Maltase Deficiency | Rare Disease Advisor Pompe disease, also known as acid maltase deficiency or glycogen storage disease type II, is a rare genetic disorder characterized by a deficiency or absence of the lysosomal acid alpha

Updates in Pompe Disease: Overview and Emerging Overview1-3 Pompe disease (aka glycogen storage disease type II [GSD II] or acid maltase deficiency [AMD]) is a rare autosomal recessive genetic disorder1,2

Pompe Disease | Mount Sinai - New York Pompe disease is caused by mutations in the GAA gene. Mutations in the GAA gene result in the deficiency of an enzyme, acid alpha-glucosidase, that is necessary for the breakdown of a

Pompe Disease | LSDSS India Pompe disease is an inherited disorder caused by the buildup of a complex sugar called glycogen in the body's cells. The accumulation of glycogen in certain organs and tissues, especially

Pompe Disease - Causes, Symptoms, Diagnosis, and Treatment Definition Pompe Disease is a genetic disorder caused by the deficiency of an enzyme called acid alpha-glucosidase (GAA). This enzyme is essential for breaking down

Pompe Warrior Foundation The mission of the Pompe Warrior Foundation is to promote research, educate, and empower individuals and families affected by Pompe Disease and other Lysosomal Storage Diseases.

Pompe Disease | UPMC Children's Hospital of Pittsburgh Pompe disease is a rare genetic condition that weakens a child's heart and muscles. Prompt detection is vital. Find expert care at UPMC Children's-Pittsburgh

Glycogen storage disease type II - Glycogen storage disease type II, also known as Pompe disease or acid maltase deficiency disease, is an inherited lysosomal storage disorder characterized by abnormal

Newborn Screening - Pompe Disease - EveryLife Foundation for Rare Diseases General Information Pompe disease is a rare, progressive, and life-threatening genetic lysosomal storage disorder that affects many parts of the body including the muscles, heart, and central

Pompe Disease Diet and Nutrition - Rare Disease Advisor Pompe disease, also referred to as glycogen storage disease type II, is a genetic myopathy that results from a deficiency of the enzyme acid alpha-glucosidase. As a result of the deficiency,

Pompe Disease - Boston Children's Hospital Pompe disease is caused by a genetic mutation that causes a buildup of complex sugars in the body’s tissues. This buildup makes it difficult for children with the disease to function normally.

What Is Pompe Disease? Symptoms, Causes, Diagnosis, and Pompe disease is a rare, inherited genetic disorder in which the body cannot break down glycogen, leading to muscle weakness and an enlarged heart

Pompe Disease - Practical Neurology Pompe disease is a rare metabolic myopathy caused by a deficiency of the alpha-glucosidase (GAA) enzyme, which is involved the breakdown of glycogen. The GAA deficiency

Gene Therapy for Infantile-Onset Pompe’s Disease Pompe’s disease is a lysosomal storage disorder that manifests as a metabolic myopathy and is almost invariably associated with severe and progressive physical disability

Pompe Disease | ASGCT - American Society of Gene & Cell Therapy Pompe disease occurs when the genes that instruct our cells to create the GAA enzyme are faulty. The GAA enzyme’s job is to break down complex molecules like glycogen,

A Beacon of Hope Found for the Future of Pompe Disease Bruce is an advocate for Pompe disease. Confined to a wheelchair with complete paralysis, and being told he would never walk again, set Bruce in literal motion to engage in a

Pompe Disease Pathophysiology - Rare Disease Advisor Pompe disease is a rare autosomal recessive disorder also known as Type II glycogen storage disease (GSDII). 1,2 This is a severe multisystemic metabolic disorder that is often fatal and

Pompe Disease - BrainFacts Pompe Disease Pompe disease is a rare (estimated at 1 in every 40,000 births), inherited and often fatal disorder that disables the heart and skeletal muscles. It is caused by mutations in a

Pompe disease symptoms: Early signs to look out for – Pompe Pompe disease symptoms can vary, depending on age of onset and disease type. Common symptoms include muscle weakness and breathing issues

Pompe Disease: a Clinical, Diagnostic, and Therapeutic Overview This review summarizes the clinical presentation and provides an update on the current strategies for diagnosis of Pompe disease. We will review the available treatment options. We examine

MDA-MCDA 17001 Flash Card DMD v9 Pompe is classified as a metabolic muscle disorder, one of a group of diseases that interferes with processing and storage of complex sugars (carbohydrates). The build-up of sugar molecules

What is Pompe disease? | Pompe Disease News Pompe disease is a rare genetic disorder marked by the buildup inside cells of the sugar molecule glycogen, which damages organs and tissues

Glycogen Storage Disease, Type II (Pompe Disease) - Learn more about glycogen storage disease, type II (Pompe Disease). Find out about newborn screening for Pompe Disease, signs and symptoms, what happens next, and

Lysosomal acid alpha-glucosidase deficiency (Pompe disease - UpToDate Comprehensive guide on lysosomal acid alpha-glucosidase deficiency (Pompe disease), covering its clinical manifestations, diagnosis, and management strategies

Pompe Disease News Home | Pompe Disease News Get the latest news on Pompe disease, its causes, symptoms, diagnosis, and treatments. Hear patient and caregiver voices from our growing Pompe community

Pompe Disease | Nemours KidsHealth Pompe disease is a rare genetic condition that causes muscle weakness that gets worse over time. It can have a serious effect on many of the body's systems. Pompe disease is also called

What is Pompe Disease? What are the symptoms of Pompe Pompe disease is an inherited disorder characterized by muscle weakness, respiratory insufficiency and, in some forms, enlargement of the heart.1 It involves deficiency of the

Pompe | Baby's First Test | Newborn Screening | Baby Health Pompe is an inherited condition that affects many different parts of the body. It is considered a lysosomal storage disorder because people with Pompe have lysosomes (the recycling center

Pompe Disease | Glycogen Storage Disease Type II | Duke Health Pompe disease is a genetic disease that occurs when a specific enzyme (acid alpha-glucosidase) is absent or the body doesn't produce enough. This results in the buildup of a complex sugar

Pompe Consortium | Pompe Disease Ecosystem & Database The Pompe Consortium embodies the intersection of the Pompe Disease ecosystem—patients, academia, industry, advocates, researchers, regulators—with the explicit purpose to

Pompe Disease - GeneReviews® - NCBI Bookshelf Pompe disease can be classified by age of onset, organ involvement, severity, and rate of progression into infantile-onset Pompe disease (IOPD) (i.e., individuals with onset

Pompe Disease - Stanford Medicine Pompe disease, (also known as Glycogen Storage Disease type II), is a type of lysosomal storage disease, meaning there is an issue in how parts of the cell (lysosomes) break down certain

About Pompe disease - Astellas Gene Therapies Pompe disease Pompe disease (also known as glycogen storage disease type II or acid maltase deficiency) is a rare, genetic, metabolic disorder. Pompe disease is caused by

About Pompe Disease - United Pompe Foundation Pompe Disease A progressive, multisystemic, debilitation, and often fatal muscular disease Single disease continuum presenting with variable rates of progression Presentation ranges

How is Pompe disease diagnosed? | Pompe Disease News A diagnosis of Pompe disease typically requires testing the activity of the acid alpha-glucosidase enzyme as a first-line method. This enzyme normally breaks down a

How Is Pompe Disease Treated? - WebMD To get the best care for Pompe disease, you need treatment from a team of health care professionals. Here’s what treatment for you or your child may include

Pompe Disease - UF Health Pompe Disease Registry The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the

Pompe Disease | Lurie Children's A rare genetic disease of the heart and skeletal muscles caused by a lack alpha-glucosidase which results in the build-up of glycogen, disabling heart and skeletal muscles

NEXVIAZYME® (avalglucosidase alfa-ngpt) | Late-Onset Pompe Learn about NEXVIAZYME® (avalglucosidase alfa-ngpt), an M6P-enriched enzyme replacement therapy for late-onset Pompe disease (LOPD). Please see Important Safety Information,

Pompe Disease An overview of Pompe disease, including pathophysiology, disease spectrum, challenges in diagnosis, and testing and disease registry resources for providers

Home - AMDA Pompe 5 days ago This past May, our hearts broke twice. Within just two weeks, the Pompe community said goodbye to two extraordinary advocates: Maryze Schoneveld van der Linde with the IPA,

You have Pompe disease, it doesn't have you Welcome to Pompeandyou.com, an educational community that provides information and resources to help you along your journey with Pompe disease

Pompe Disease - Lysosomal Center Pompe disease is a Lysosomal disorder caused by the accumulation of a complex sugar called glycogen in muscles and other organs and tissues. The lack of acid alpha-glucosidase, the

Management of Pompe disease alongside and beyond ERT: a Pompe disease is a lysosomal

storage disorder that primarily affects muscles, and its natural history has been transformed over the past 20 years by therapies designed to restore the

Pompe Disease Awareness: Symptoms, Causes, and Treatment Learn about Pompe disease—a rare genetic disorder affecting the heart and skeletal muscles. Explore symptoms, causes, and treatment options

Pompe disease treatment options | Pompe Disease News There is no cure for Pompe disease, but treatments — including Lumizyme, Nexviazyme, and Pombiliti + Opfolda — can slow disease progression

The Physician's Guide to Pompe Disea What is Pompe Disease? Pompe disease is an autosomal recessively inherited metabolic disorder that affects one of more than 40 lysosomal enzymes. Patients with Pompe disease

Home - AMDA Pompe The Acid Maltase Deficiency Association formed to assist in funding research and to promote public awareness of Acid Maltase Deficiency, also known as Pompe's Disease

Symptoms - International Pompe Association Pompe disease is a rare genetic disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA), leading to an abnormal accumulation of glycogen in various tissues of the

Pompe Disease - Metabolic Support UK Pompe Disease is caused by a problem in the GAA gene. This gene provides instructions for the enzyme acid alpha-glucosidase (acid maltase) which breaks down glycogen. This process is

Pompe Disease - Acid Maltase Deficiency | Rare Disease Advisor Pompe disease, also known as acid maltase deficiency or glycogen storage disease type II, is a rare genetic disorder characterized by a deficiency or absence of the lysosomal acid alpha

Updates in Pompe Disease: Overview and Emerging Treatment Overview1-3 Pompe disease (aka glycogen storage disease type II [GSD II] or acid maltase deficiency [AMD]) is a rare autosomal recessive genetic disorder1,2

Pompe Disease | Mount Sinai - New York Pompe disease is caused by mutations in the GAA gene. Mutations in the GAA gene result in the deficiency of an enzyme, acid alpha-glucosidase, that is necessary for the breakdown of a

Pompe Disease | LSDSS India Pompe disease is an inherited disorder caused by the buildup of a complex sugar called glycogen in the body's cells. The accumulation of glycogen in certain organs and tissues, especially

Pompe Disease - Causes, Symptoms, Diagnosis, and Treatment Definition Pompe Disease is a genetic disorder caused by the deficiency of an enzyme called acid alpha-glucosidase (GAA). This enzyme is essential for breaking down

Pompe Warrior Foundation The mission of the Pompe Warrior Foundation is to promote research, educate, and empower individuals and families affected by Pompe Disease and other Lysosomal Storage Diseases.

Pompe Disease | UPMC Children's Hospital of Pittsburgh Pompe disease is a rare genetic condition that weakens a child's heart and muscles. Prompt detection is vital. Find expert care at UPMC Children's-Pittsburgh

Glycogen storage disease type II - Glycogen storage disease type II, also known as Pompe disease or acid maltase deficiency disease, is an inherited lysosomal storage disorder characterized by abnormal

Newborn Screening - Pompe Disease - EveryLife Foundation for Rare Diseases General Information Pompe disease is a rare, progressive, and life-threatening genetic lysosomal storage disorder that affects many parts of the body including the muscles, heart, and central

Pompe Disease Diet and Nutrition - Rare Disease Advisor Pompe disease, also referred to as glycogen storage disease type II, is a genetic myopathy that results from a deficiency of the enzyme acid alpha-glucosidase. As a result of the deficiency,

Pompe Disease - Boston Children's Hospital Pompe disease is caused by a genetic mutation that

causes a buildup of complex sugars in the body’s tissues. This buildup makes it difficult for children with the disease to function normally.

What Is Pompe Disease? Symptoms, Causes, Diagnosis, and Pompe disease is a rare, inherited genetic disorder in which the body cannot break down glycogen, leading to muscle weakness and an enlarged heart

Pompe Disease - Practical Neurology Pompe disease is a rare metabolic myopathy caused by a deficiency of the alpha-glucosidase (GAA) enzyme, which is involved the breakdown of glycogen. The GAA deficiency

Gene Therapy for Infantile-Onset Pompe’s Disease Pompe’s disease is a lysosomal storage disorder that manifests as a metabolic myopathy and is almost invariably associated with severe and progressive physical disability

Pompe Disease | ASGCT - American Society of Gene & Cell Therapy Pompe disease occurs when the genes that instruct our cells to create the GAA enzyme are faulty. The GAA enzyme’s job is to break down complex molecules like glycogen,

A Beacon of Hope Found for the Future of Pompe Disease Treatment Bruce is an advocate for Pompe disease. Confined to a wheelchair with complete paralysis, and being told he would never walk again, set Bruce in literal motion to engage in a

Pompe Disease Pathophysiology - Rare Disease Advisor Pompe disease is a rare autosomal recessive disorder also known as Type II glycogen storage disease (GSDII). 1,2 This is a severe multisystemic metabolic disorder that is often fatal and

Pompe Disease - BrainFacts Pompe Disease Pompe disease is a rare (estimated at 1 in every 40,000 births), inherited and often fatal disorder that disables the heart and skeletal muscles. It is caused by mutations in a

Pompe disease symptoms: Early signs to look out for – Pompe Pompe disease symptoms can vary, depending on age of onset and disease type. Common symptoms include muscle weakness and breathing issues

Related to pompe disease enzyme replacement therapy

Enzyme-replacement therapy improves outcomes in Pompe disease (Healio1y) Please provide your email address to receive an email when new articles are posted on . Researchers analyzed 19 children with Pompe disease seen at a Texas-based children’s hospital

Enzyme-replacement therapy improves outcomes in Pompe disease (Healio1y) Please provide your email address to receive an email when new articles are posted on . Researchers analyzed 19 children with Pompe disease seen at a Texas-based children’s hospital

Duke scientists join team involved in the first use of fetal therapy for Pompe disease (News Medical2y) Experts at Duke Health were among a multi-national team involved in treating a fetus for infantile-onset Pompe disease using an enzyme replacement therapy - a first in the world. The case, reported

Duke scientists join team involved in the first use of fetal therapy for Pompe disease (News Medical2y) Experts at Duke Health were among a multi-national team involved in treating a fetus for infantile-onset Pompe disease using an enzyme replacement therapy - a first in the world. The case, reported

Duke Health creates new therapy to save babies while in utero (WRAL2y) Experts at Duke Health pioneered the initial research and treatments for young children who are diagnosed with a rare and typically fatal condition called Pompe Disease. Their research has led to the

Duke Health creates new therapy to save babies while in utero (WRAL2y) Experts at Duke Health pioneered the initial research and treatments for young children who are diagnosed with a rare and typically fatal condition called Pompe Disease. Their research has led to the

Pompe Disease Market Analysis Report 2025-2035: Enzyme Replacement Therapies and Approvals of Myozyme and Nexviazyme Drive Steady Growth (1d) Pompe disease is a rare genetic disorder resulting from GAA gene mutations, leading to acid alpha-glucosidase deficiency

and glycogen buildup. Key symptoms include progressive muscle weakness and

Pompe Disease Market Analysis Report 2025-2035: Enzyme Replacement Therapies and Approvals of Myozyme and Nexviazyme Drive Steady Growth (1d) Pompe disease is a rare genetic disorder resulting from GAA gene mutations, leading to acid alpha-glucosidase deficiency and glycogen buildup. Key symptoms include progressive muscle weakness and

Sanofi’S Investigational Enzyme Replacement Therapy Shows Clinically Meaningful Improvement In Critical Manifestations Of Late-Onset Pompe Disease (Reuters5y) * U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED BREAKTHROUGH THERAPY AND FAST TRACK DESIGNATIONS TO AVALGLUCOSIDASE ALFA FOR TREATMENT OF PATIENTS WITH POMPE DISEASE. * Avalglucosidase alfa

Sanofi’S Investigational Enzyme Replacement Therapy Shows Clinically Meaningful Improvement In Critical Manifestations Of Late-Onset Pompe Disease (Reuters5y) * U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED BREAKTHROUGH THERAPY AND FAST TRACK DESIGNATIONS TO AVALGLUCOSIDASE ALFA FOR TREATMENT OF PATIENTS WITH POMPE DISEASE. * Avalglucosidase alfa

Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease (Business Insider1y) WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for

Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease (Business Insider1y) WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for

Promising Results in First Test of In Utero Enzyme-Replacement Therapy (MedPage Today2y) Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The first test

Promising Results in First Test of In Utero Enzyme-Replacement Therapy (MedPage Today2y) Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The first test

FDA approves oral therapy for late-onset Pompe disease (Healio2y) Please provide your email address to receive an email when new articles are posted on . The FDA has approved a two-part combination therapy in 65 mg capsules to treat adults with late-onset Pompe

FDA approves oral therapy for late-onset Pompe disease (Healio2y) Please provide your email address to receive an email when new articles are posted on . The FDA has approved a two-part combination therapy in 65 mg capsules to treat adults with late-onset Pompe

Back to Home: https://www-01.massdevelopment.com